메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
김동성 (순천향대학교 서울병원 피부과) 김기담 (Department of Dermatology Soonchunhyang University Seoul Hospital Soonchunhyang University College of Medicine Seoul Korea) 허재영 (순천향대학교 의과대학 순천향서울병원) 최유성 (Department of Dermatology Soonchunhyang University Hospital Seoul Korea) 조문균 (Department of Dermatology Soonchunhyang University Seoul Hospital Soonchunhyang University College of Medicine Seoul Korea) 김수영 (Department of Dermatology Soonchunhyang University Seoul Hospital Soonchunhyang University College of Medicine Seoul Korea)
저널정보
대한건선학회 대한건선학회지 대한건선학회지 제20권 제1호
발행연도
2023.6
수록면
35 - 38 (4page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Secukinumab is a humanized monoclonal antibody against IL-17A approved for psoriasis and psoriatic arthritis. Recently, various eczematous reactions associated with IL- 17 inhibitor were reported as the most common paradoxical reaction. Although its mechanism is not well known, blocking the Th1/Th17 pathway could induce a paradoxical Th2 axis activation, which manifests as atopic eczema. A 57-year-old female patient presented with 30-year lasting chronic plaque psoriasis on her scalp, trunk, and both extremities. She had a history of asthma and denied any personal or familial history of atopic dermatitis. Initially, the patient was treated with cyclosporine for 1 year followed by 6 months of methotrexate, but only a partial response was achieved. She started receiving secukinumab and after 3rd injection, psoriasis improved while developing severe pruritic eczematous eruption. Secukinumab was discontinued after the 5th injection due to eczema aggravation and systemic therapy with cyclosporine was started to manage the paradoxical eczematous reaction.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0